Advertisement
Australia markets close in 1 hour 6 minutes
  • ALL ORDS

    7,959.70
    -15.10 (-0.19%)
     
  • ASX 200

    7,716.10
    -8.20 (-0.11%)
     
  • AUD/USD

    0.6603
    -0.0015 (-0.22%)
     
  • OIL

    78.17
    -0.28 (-0.36%)
     
  • GOLD

    2,338.00
    -11.10 (-0.47%)
     
  • Bitcoin AUD

    100,499.32
    +273.37 (+0.27%)
     
  • CMC Crypto 200

    1,405.90
    -11.97 (-0.84%)
     
  • AUD/EUR

    0.6167
    -0.0011 (-0.17%)
     
  • AUD/NZD

    1.0781
    +0.0016 (+0.15%)
     
  • NZX 50

    11,690.27
    -174.62 (-1.47%)
     
  • NASDAQ

    19,659.80
    +82.90 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.68 (-1.44%)
     
  • Hang Seng

    17,978.30
    +36.52 (+0.20%)
     
  • NIKKEI 225

    37,987.42
    -827.14 (-2.13%)
     

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com